Acrivon Therapeutics Inc (ACRV)

Dec 09, 2025

Holdings of Acrivon Therapeutics Inc (ACRV) are aligned with the stars - setenews.com

Dec 09, 2025

Dec 06, 2025

Volume Report: How Acrivon Therapeutics Inc stock reacts to bond yields2025 Historical Comparison & Growth-Oriented Investment Plans - moha.gov.vn

Dec 06, 2025

Dec 06, 2025

What drives Acrivon Therapeutics Inc stock priceTrendline Breakouts & Low Cost Capital Growth - earlytimes.in

Dec 06, 2025

Dec 06, 2025

SBI Cards and Payment Services Limited Stages Intraday Comeback Trend Change - earlytimes.in

Dec 06, 2025

Dec 04, 2025

How Acrivon Therapeutics Inc. stock reacts to bond yieldsBond Market & AI Forecasted Entry and Exit Points - Newser

Dec 04, 2025

Dec 02, 2025

ACRV SEC FilingsAcrivon Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Dec 02, 2025

Dec 02, 2025

Get in on Acrivon Therapeutics Inc’s (ACRV) buy-in window today! - setenews.com

Dec 02, 2025

Nov 29, 2025

H.C. Wainwright Initiates Coverage on Acrivon Therapeutics (ACRV) With “Buy” Rating and $19 PT - Insider Monkey

Nov 29, 2025

Nov 27, 2025

Investors in cash trouble should check out Acrivon Therapeutics Inc (ACRV) - Setenews

Nov 27, 2025

Nov 27, 2025

HC Wainwright Reiterates Buy Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Nov 27, 2025

Nov 26, 2025

Acrivon Therapeutics' (ACRV) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Nov 26, 2025

Nov 25, 2025

Chmn Blume-Jensen Surrenders 19,904 Of Acrivon Therapeutics Inc [ACRV] - TradingView

Nov 25, 2025

Nov 25, 2025

Citadel Advisors LLC Acquires Additional Shares in Acrivon Therapeutics Inc - GuruFocus

Nov 25, 2025

Nov 25, 2025

ACRV: HC Wainwright Reiterates 'Buy' Rating and $19 Price Target - GuruFocus

Nov 25, 2025

Nov 25, 2025

HC Wainwright & Co. Reiterates Acrivon Therapeutics (ACRV) Buy Recommendation - Nasdaq

Nov 25, 2025

Nov 25, 2025

Optimistic Buy Rating for Acrivon Therapeutics, Inc. Driven by Promising ACR-368 Trial Developments - TipRanks

Nov 25, 2025

Nov 25, 2025

Acrivon insiders report RSU tax withholding, 2.05M shares held - Stock Titan

Nov 25, 2025

Nov 22, 2025

Acrivon Therapeutics (NASDAQ:ACRV) Stock Rating Upgraded by Wall Street Zen - MarketBeat

Nov 22, 2025

Nov 21, 2025

Cantor Fitzgerald Has Positive View of ACRV FY2025 Earnings - MarketBeat

Nov 21, 2025

Nov 21, 2025

Will Acrivon Therapeutics Inc. stock see PE expansionWeekly Trade Recap & High Accuracy Trade Alerts - newser.com

Nov 21, 2025

Nov 21, 2025

Research Analysts Issue Forecasts for ACRV FY2025 Earnings - Defense World

Nov 21, 2025

Nov 19, 2025

Brokerages Set Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Target Price at $11.00 - Defense World

Nov 19, 2025

Nov 18, 2025

There is no way Acrivon Therapeutics Inc (ACRV) can keep these numbers up - Setenews

Nov 18, 2025

Nov 18, 2025

Acrivon Therapeutics Form 4: COO tax withholding on 613 RSU shares - Stock Titan

Nov 18, 2025

Nov 17, 2025

Acrivon Therapeutics stock rating reiterated by Citizens with $13 target - Investing.com Nigeria

Nov 17, 2025

Nov 16, 2025

Is Acrivon Therapeutics Inc. stock attractive for hedge fundsMarket Performance Recap & Capital Efficient Trade Techniques - newser.com

Nov 16, 2025

Nov 16, 2025

Will Acrivon Therapeutics Inc. stock split attract more investors2025 Momentum Check & Weekly Sector Rotation Insights - newser.com

Nov 16, 2025

Nov 16, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Acrivon Therapeutics, Inc. (ACRV) - The Globe and Mail

Nov 16, 2025

Nov 14, 2025

Acrivon Therapeutics Narrows Losses And Draws Analyst Support - Finimize

Nov 14, 2025

Nov 14, 2025

Positive Outlook and Buy Rating for Acrivon Therapeutics, Inc. Based on Promising Clinical Data and Strategic Advancements - TipRanks

Nov 14, 2025

Nov 14, 2025

Acrivon Therapeutics Shrinks Losses And Draws Analyst Optimism - Finimize

Nov 14, 2025

Nov 14, 2025

Analysts’ Top Healthcare Picks: Acrivon Therapeutics, Inc. (ACRV), Sera Prognostics (SERA) - The Globe and Mail

Nov 14, 2025

Nov 14, 2025

Is Acrivon Therapeutics Inc. stock supported by strong cash flowsMarket Trend Report & Community Verified Watchlist Alerts - newser.com

Nov 14, 2025

Nov 14, 2025

Acrivon Therapeutics Reports Q3 2025 Financial Results - TipRanks

Nov 14, 2025

Nov 13, 2025

Acrivon Therapeutics Advances ACR-368 in Phase 2b Trial for Endometrial Cancer and Prepares for Initial Data on ACR-2316 - Quiver Quantitative

Nov 13, 2025